Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
In March 2025, Roche entered into an outstanding licensing agreement and collaboration with Zealand Pharma for co-commercializing and co-developing petrelintide as a standalone therapy and a fixed-dose combination with Roches lead incretin asset CT-388
Early research suggests that microneedled patches and other novel delivery systems could theoretically work, but human efficacy and safety data remain limited
Heres what you need to know: Short-Term Results (36 months): Most people lose 510% of their body weight
Always request a batch-specific Certificate of Analysis showing HPLC chromatography, mass spectrometry identity confirmation, and water content analysis
Nausea Often Happens During Dose Escalation Many people notice nausea when they first start the medication or when their dose increases
